dat.xu: A Network Meta-Analysis on Immune Checkpoint Inhibitor Drugs

In altmeta: Alternative Meta-Analysis Methods

A Network Meta-Analysis on Immune Checkpoint Inhibitor Drugs

Description

This network meta-analysis investigates the effects of seven immune checkpoint inhibitor (ICI) drugs on all-grade treatment-related adverse events (TrAEs). It aimed to provide a safety ranking of the ICI drugs for the treatment of cancer.

Usage

data("dat.xu")

Format

A dataset of network meta-analysis with binary outcomes, containing 23 studies and 7 treatments.

sid

study IDs.

tid

treatment IDs.

r

event counts.

n

sample sizes.

Details

Treatment IDs represent: 1) conventional therapy; 2) nivolumab; 3) pembrolizumab; 4) two ICIs; 5) ICI and conventional therapy; 6) atezolizumab; and 7) ipilimumab.

Source

Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J (2018). "Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis." BMJ, 363, k4226. <\Sexpr[results=rd]{tools:::Rd_expr_doi("10.1136/bmj.k4226")}>

altmeta documentation built on Sept. 11, 2024, 9 p.m.